HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cady, R. K. Articles by Webster, C. J. Search for Related Content PubMed PubMed Citation Articles by Cady, R. K. Articles by Webster, C. J.

Efficacy of subcutaneous sumatriptan in repeated episodes of migraine

Shealy Institute (Dr. Cady), Springfield, MO; the Department of Neurology (Dr. Dexter), University of Missouri Hospital and Clinics, Columbia, MO; Menninger Clinic (Dr. Sargent), Topeka, KS; the Department of Neurology (Dr. Markley), The Medical Center of Central Massachusetts, Worcester, MA; and Glaxo, Inc (Dr. Osterhaus, and C.J. Webster), Research Triangle Park, NC.

This double-blind, placebo-controlled, multicenter, crossover study investigated the efficacy and tolerability of sumatriptan administered for up to three separate migraine attacks. One hundred twenty adults received sumatriptan (SC, 6 mg; three attacks) and placebo (one attack). Patients completed questionnaires assessing the impact of migraine on their lives and the performance of sumatriptan relative to their usual acute therapies. Sumatriptan statistically outperformed placebo on all efficacy measures, including pain severity; presence/absence of nausea, vomiting, phonophobia, and photophobia; rescue medication use; and clinical disability. Efficacy was consistently maintained with repeated administration. For all attacks, pain relief 90 minutes postdose occurred in 86% to 90% of sumatriptan-treated patients, compared with 9% to 38% of placebo-treated patients. Sumatriptan was well tolerated, and the frequency and severity of adverse events did not change with repeated administration. Patients' perceptions of sumatriptan were consistent with clinical data demonstrating the drug's high degree of efficacy and tolerability.

Address correspondence and reprint requests to Dr. Roger K. Cady, Shealy Institute, 1328 East Evergreen Street, Springfield, MO 65803.

Supported by a grant from Glaxo Research Institute.

Received October 7, 1992. Accepted for publication in final form November 20, 1992.

This article has been cited by other articles:

				R. K. Cady, J. Rubino, D. Crummett, and T. W. Littlejohn III Oral Sumatriptan in the Treatment of Recurrent Headache Arch Fam Med, September 1, 1994; 3(9): 766 - 772. [Abstract] [PDF]